Does walking lower blood pressure? A Cochrane review of 73 trials has the number

The review is Walking for hypertension, published in the Cochrane Database of Systematic Reviews on 24 February 2021. Its inclusion criteria were randomized controlled trials in people aged 16 and over comparing a walking intervention against a non-intervention control. Seventy-three trials met them, covering 5,763 participants in 22 countries, aged 16 to 84, with roughly 1.5 times as many women as men.

Despite the title, the population is not restricted to people with hypertension. The review's types-of-participants section says both hypertensive and normotensive adults aged 16 years and over, which matters for reading the result onto yourself.

This is the part most articles leave out, and it is the only part you can act on. The review describes what the trials actually asked people to do: most walking was done at home or in the community, most of it supervised where supervision was reported, the average intervention ran 15 weeks, average walking time was 153 minutes per week, and most walking was of moderate intensity.

The review broke the result down by age band, and the certainty ratings are not the same across bands. Printing the point estimate without the rating would misrepresent the evidence, so both are here.

If you are between 41 and 60, which is the middle of this site's audience, the honest summary is that walking probably helps and the evidence supporting the size of the effect in your band is rated low certainty. That is not a reason to skip the walk. It is a reason to be suspicious of anyone quoting a precise figure for your decade without the rating attached.

The review tested this rather than assuming it. It compared the effect in normotensive participants against those with higher readings and found a similar magnitude in each: -4.14 mmHg against a normotensive comparison and -4.24 mmHg against a hypertensive one, with no significant difference between subgroups. Its discussion concludes that given the similar reduction seen among normotensive and hypertensive people, and the weak association between baseline and change in blood pressure, the effect of walking is similarly beneficial to both groups.

The thresholds the review used for those categories were systolic below 130 mmHg for normotensive, 130 or above for high normal, and 140 or above for hypertension. Those cut points sit close to the categories in our guide to the 2025 blood pressure ranges.

Here the honest answer requires care, because it is easy to inflate. The review's authors write that the reductions they found were of greater magnitude than a reduction of 2 mmHg systolic and could be considered clinically significant. That is their phrasing and their hedge, and it is worth keeping both.

The 2 mmHg benchmark is not the review's own finding. The review takes it from another paper it cites, which we have not read, so the accurate sentence is that the review's authors considered the effect clinically significant against a benchmark they cite from elsewhere. It is also worth saying plainly what these trials measured: resting blood pressure after programs averaging 15 weeks. None of them measured heart attacks, strokes or deaths. Anyone converting 4 mmHg into a number of prevented events is doing arithmetic the trials did not support.

Cochrane explains its own downgrade. The certainty on systolic pressure was rated moderate rather than high because of lack of clarity around randomization procedures, allocation concealment and blinding of participants, personnel and outcome assessors, and because of some inconsistency across trials related to differences in populations and interventions.

One further detail deserves printing, because it is the kind of thing usually buried. A sensitivity analysis restricted to trials at low risk of bias showed a non-significant reduction in diastolic blood pressure. The diastolic finding is the weaker half of this review, and it does not survive the strictest cut.

A separate network meta-analysis in the British Journal of Sports Medicine pooled 270 randomized trials and 15,827 participants comparing exercise modes. Its pairwise results put isometric exercise training well ahead: -8.24/-4.00 mmHg, against -4.49/-2.53 for aerobic exercise training, -4.55/-3.04 for dynamic resistance training, -6.04/-2.54 for combined training and -4.08/-2.50 for high-intensity interval training. On its ranking metric, isometric training came first and aerobic training fourth of five.

One caveat has to travel with those numbers. Walking is not one of that analysis's categories; it sits inside aerobic exercise training. So the fair statement is that the broad category containing walking ranked fourth of five, not that walking did. The practical reading is that if lowering blood pressure is the only goal, isometric work such as wall squats has the larger measured effect, and walking's advantage is that people actually keep doing it for 15 weeks.

Context for both: an American Heart Association scientific statement holds that for patients with mildly or moderately elevated blood pressure and cholesterol, lifestyle-only approaches are the first line of therapy, and estimates that 21 percent of US adults have mild to moderate risk blood pressure and should receive lifestyle-only first-line treatment.

Walk at moderate intensity, three to five times a week, 20 to 40 minutes at a time, aiming at about 150 minutes a week, and give it three months before judging. Measure with a validated upper-arm cuff at the same time of day, before and after, because a 4 mmHg change is smaller than the noise in a single casual reading. If your pressure is in the stage 1 or stage 2 range, this sits alongside rather than instead of what your clinician recommends, and our guide to what each blood pressure category triggers covers where the medication thresholds now fall.

Check before starting a new exercise program if you have known heart disease, chest pain on exertion, unexplained breathlessness, or a blood pressure above 180 over 120. Otherwise, walking needs no clearance. Bring a fortnight of home readings to your next review rather than a single number, and ask what your target is, since the 2025 guideline sets an overarching goal of below 130 over 80 for most adults.